Cerezyme® is supplied as a sterile, non-pyrogenic lyophilized product. Cerezyme® 400 unit vial is supplied in single-use, clear Type I glass vials. The 400 unit vial closure consists of a siliconized butyl stopper and an aluminum seal with a red plastic flip-off cap.
In the U.S., Cerezyme can be ordered directly from Genzyme or one of our distributors.
A patient's insurance coverage may dictate how drug will be ordered. If you are unsure or would like more information please call 1-800-745-4447, Option 3 to speak with a Genzyme Case Manager.
Cerezyme NDC code
400 unit vial
Cerezyme Fact Sheet
Ordering Direct from Genzyme
If you would like to order Cerezyme directly from Genzyme, which includes ordering through a wholesaler, please contact a Genzyme Account Manager for more information.
Genzyme Account Managers can be reached at:
1-800-745-4447, Option 1
Monday through Friday, 8:00 AM to 6:00 PM ET
Please Note the Following:
- For next day delivery, orders must be received by 5:00 p.m. ET, Monday through Thursday, excluding holidays. All orders must be confirmed via the telephone.
- New customers must establish an account with a Genzyme Account Manager before orders can be shipped. Please call 1-800-745-4447, Option 1 to set up your account well in advance of your patient's first infusion to ensure timely delivery.
To obtain a copy of our returned goods policy or pricing information for Cerezyme, please contact a Genzyme Account Manager at 1-800-745-4447, Option 1.
When you order Cerezyme directly from Genzyme, your site will be assigned a personal Account Manager who is dedicated to ensuring that the logistics of obtaining Cerezyme are as seamless as possible.
After hours or weekend emergencies? Our on-call Account Manager is available to help in emergency situations through our answering service.
Shipping with Care
Cerezyme orders ship Monday through Thursday, 8am — 5pm ET from Genzyme's facility in Framingham, MA. Shipments for our direct accounts are sent via Federal Express, Priority One First Overnight for next day delivery. Please keep this timeframe in mind when placing orders and remember to place orders well in advance of holidays to ensure timely delivery.
All Cerezyme orders from Genzyme are carefully packaged to maintain the proper temperature during shipment.
Indication & Usage
Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:
- bone disease
- hepatomegaly or splenomegaly
Important Safety Information
Approximately 15% of patients have developed IgG antibodies to Cerezyme during the first year of therapy. Approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity, and these patients have a higher risk of hypersensitivity. It is suggested that patients be monitored periodically for IgG antibody formation during the first year of treatment.
Hypersensitivity has also been observed in patients without detectable IgG antibodies. Symptoms suggestive of hypersensitivity have been noted in approximately 6.6% of all patients, and anaphylactoid reactions in less than 1%. Treatment with Cerezyme should be approached with caution in patients who have exhibited hypersensitivity symptoms such as pruritus, flushing, urticarial, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Pre-treatment with antihistamines and/or corticosteroids and a reduced rate of infusion may allow continued treatment in most patients.
In less than 1% of patients, pulmonary hypertension and pneumonia have been observed during treatment with Cerezyme. These are known complications of Gaucher disease regardless of treatment. Patients with respiratory symptoms in the absence of fever should be evaluated for the presence of pulmonary hypertension.
Approximately 13.8% of patients have experienced adverse events related to treatment with Cerezyme. Some of these are injection site reactions such as discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of venipuncture. Additional adverse reactions that have been reported include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Transient peripheral edema has also been reported for this therapeutic class of drug.
To report suspected adverse reactions, contact Genzyme at 800-745-4447, option 2 or FDA at 800-FDA-1088 or http://www.fda.gov/Safety/MedWatch
Please see Full Prescribing Information (PDF).